Replies to post #940 on Synaptogenix Inc (SNPX)

[kld2]

Btw, in my last post, instead of saying, "Anyone like to take a stab at..." I said "jab" at. Lol! I'm revealing my true colors!

[kld2]

In answer to my question about lack of efficacy in Ph2a trial, Michael Bigger replied: One dose.

Shows what I know. Guess I would like to know: why not two--or three--or four doses, while you're at it?

[SF Wolf]

kld, I doubt anybody on this board has the scientific expertise to evaluate the biochemistry of Bryostatin and Dr. Alkons research.

Dr. Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, in her presentation at the Noble Financial Capital on 1/30/17 did state:

“we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.”

So, the company is hypothesizing that success in late stage patients will translate into an early treatment for AD.

If Dr. Wilke is right then John Carroll, editor at END POINTS NEWS, in an article last week discussing the recent AD research failure at Lundbeck and problems at Axovant states what we are all hoping for with Neurotrope:

“If a developer can get through an R&D field littered with huge failures like solanezumab and bapineuzumab and make it to the market with a drug, the payoff would be worth billions in annual revenue.”

https://endpts.com/lundbeck-reads-last-rites-on-another-failed-phiii-alzheimers-program/

[runncoach]

kld,
Bryostatin doesn't even work in animals unless there have been multiple doses, that's why it was never a concern in the 2a. The company didn't even really expect it to work with a single dose...but they had to start somewhere. Obviously multiple doses worked on all 3 compassionate use patients and for the duration of which they were treated according to the company.

[doingmybest]

I agree completely with the fact that there is virtually no human data yet, which is why I stated the current P2b is really the whole game for NTRP. The trial is almost entirely based on the underlying science and good preclinical data, which is good, but, not so deep and fairly new overall. NTRP would have never been permitted to jump to this stage if it were not for the NCI safety work prior on bryostatin. There is logic here and much passion and I appreciate the way BRNI has studied this, but, it is very, very speculative at this stage. Jumping to the P2b like they did was the fastest way to find out if they have something real, unlike BP who would have studied it much more thoroughly prior to P2b. But, micro's have to be financially thrifty and have to take more chances with trials. The trial is huge for NTRP and bryostatin. The fact that they jumped to testing moderate to severe though is simply fascinating.